A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Part 1: To study the potential safety and pharmacokinetic (blood level) effects of zidovudine
(AZT) on L-697,661; to obtain additional pharmacokinetic information in humans with
L-697,661; to study the effect of L-697,661 on hepatic enzyme induction. Part 2: To begin a
study of the antiviral activity of L-697,661.
L-697,661 is a newly identified compound that inhibits HIV replication (reproduction and
growth) in cell culture. It works together with AZT against HIV.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)